ZKN 157
Alternative Names: ZKN-157Latest Information Update: 02 Aug 2023
Price :
$50 *
At a glance
- Originator Eloxx Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Ribosomal RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 02 Aug 2023 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route) (before August 2023) (Eloxx Pharmaceuticals Pipeline, August 2023)
- 16 Nov 2022 Preclinical trials in Colorectal cancer in USA (unspecified route) prior to November 2022
- 26 Oct 2022 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the 34th EORTC-NCI-AACR Symposium (ENA-2022)